Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

Summary

This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.

Timeline

Start

2021-01-05

Primary completion

2024-09-30

Completion

2024-09-30

Publications

• Zhang P, Li S, Jia R, Hao J, Chen C, Gan S, Li J, Shen L, Lu M. Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. EClinicalMedicine. 2025 Oct 24;90:103598. doi: 10.1016/j.eclinm.2025.103598. eCollection 2025 Dec.

Drugs

Indications